Abstract

BackgroundOnce remission is achieved for patients with rheumatoid arthritis (RA), treatment down-titration should be attempted, for safety issues or economic reasons. One of the proposed strategies, recently tested in the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Abstract 171: Endovascular Thrombectomy May Be Cost-Effective for Patients With Large Core Ischemic Strokes: A Cost-Utility Analysis From the SELECT Study
Rishi Gupta ... Faris Shaker
Stroke | VOL. 51
Rishi Gupta, et. al.Rishi Gupta ... Faris Shaker
01 Feb 2020
A welfare economic approach to measure outcomes in stuttering: Comparing willingness to pay and quality adjusted life years
Anne K Bothe ... Duska M Franic
Journal of Fluency Disorders | VOL. 37
Anne K Bothe, et. al.Anne K Bothe ... Duska M Franic
10 May 2012
Abstract PD7-03: Cost-effectiveness analysis of intraoperative radiotherapy for ductal carcinoma in situ
T Gross ... L Chen
Cancer Research | VOL. 78
T Gross, et. al.T Gross ... L Chen
14 Feb 2018
Cost Effectiveness of Caplacizumab in Acquired Thrombotic Thrombocytopenic Purpura
Pranay Sinha ... Alfred Ian Lee
Blood | VOL. 136
Pranay Sinha, et. al.Pranay Sinha ... Alfred Ian Lee
05 Nov 2020
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers